JP2024500946A - 糖タンパク質viに対するナノボディ - Google Patents

糖タンパク質viに対するナノボディ Download PDF

Info

Publication number
JP2024500946A
JP2024500946A JP2023538767A JP2023538767A JP2024500946A JP 2024500946 A JP2024500946 A JP 2024500946A JP 2023538767 A JP2023538767 A JP 2023538767A JP 2023538767 A JP2023538767 A JP 2023538767A JP 2024500946 A JP2024500946 A JP 2024500946A
Authority
JP
Japan
Prior art keywords
gpvi
nanobody
binding
nanobodies
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023538767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500946A5 (cg-RX-API-DMAC7.html
Inventor
アレクサンドル スレイター、
ナタリー サラ ポールター、
マーク ロバート トマス、
スティーブ ポール ワトソン、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Birmingham
Original Assignee
University of Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Birmingham filed Critical University of Birmingham
Publication of JP2024500946A publication Critical patent/JP2024500946A/ja
Publication of JP2024500946A5 publication Critical patent/JP2024500946A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023538767A 2020-12-24 2021-12-21 糖タンパク質viに対するナノボディ Pending JP2024500946A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2020602.5A GB202020602D0 (en) 2020-12-24 2020-12-24 Nanobody
GB2020602.5 2020-12-24
PCT/EP2021/087129 WO2022136457A1 (en) 2020-12-24 2021-12-21 Nanobody to glycoprotein vi

Publications (2)

Publication Number Publication Date
JP2024500946A true JP2024500946A (ja) 2024-01-10
JP2024500946A5 JP2024500946A5 (cg-RX-API-DMAC7.html) 2024-11-06

Family

ID=74532190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023538767A Pending JP2024500946A (ja) 2020-12-24 2021-12-21 糖タンパク質viに対するナノボディ

Country Status (7)

Country Link
US (1) US20240067721A1 (cg-RX-API-DMAC7.html)
EP (1) EP4267624A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024500946A (cg-RX-API-DMAC7.html)
CN (1) CN117043191A (cg-RX-API-DMAC7.html)
CA (1) CA3203202A1 (cg-RX-API-DMAC7.html)
GB (1) GB202020602D0 (cg-RX-API-DMAC7.html)
WO (1) WO2022136457A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019685A1 (en) * 2024-07-17 2026-01-22 Harpoon Therapeutics, Inc. Her2 targeting trispecific protein for treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088531A1 (en) * 2001-12-20 2006-04-27 Smethurst Peter A Human antibodies against human glycoprotein VI and their use
JP2013514077A (ja) * 2009-12-18 2013-04-25 サノフイ GPVIに対する新規アンタゴニスト抗体および該抗体のFabフラグメントならびにこれらの使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090130021A1 (en) * 2002-06-07 2009-05-21 Gotz Munch Methods, products and uses involving platelets and/or the vasculature
WO2007091719A1 (ja) * 2006-02-07 2007-08-16 Mochida Pharmaceutical Co., Ltd. 抗gpvi抗体の併用療法及び新規医薬用途
EP1916259A1 (en) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-glycoprotein VI SCFV fragment for treatment of thrombosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088531A1 (en) * 2001-12-20 2006-04-27 Smethurst Peter A Human antibodies against human glycoprotein VI and their use
JP2013514077A (ja) * 2009-12-18 2013-04-25 サノフイ GPVIに対する新規アンタゴニスト抗体および該抗体のFabフラグメントならびにこれらの使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE: UNIPROTKB, ACCESSION: Q9HCN6・GPVI_HUMAN, [ONLINE], JPN6025041735, 5 April 2011 (2011-04-05), ISSN: 0005855867 *
PLATELETS, vol. Vol.20(4), JPN6025041734, 2009, pages 268 - 276, ISSN: 0005855866 *

Also Published As

Publication number Publication date
CN117043191A (zh) 2023-11-10
EP4267624A1 (en) 2023-11-01
WO2022136457A1 (en) 2022-06-30
US20240067721A1 (en) 2024-02-29
CA3203202A1 (en) 2022-06-30
GB202020602D0 (en) 2021-02-10

Similar Documents

Publication Publication Date Title
JP7668256B2 (ja) Dll3及びcd3に結合する二重特異性抗体構築物
AU2018261951B2 (en) Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
KR102914586B1 (ko) 메소텔린 및 cd3에 결합하는 이중특이적 항체 작제물
KR102735615B1 (ko) Egfrviii 및 cd3에 결합하는 이중특이적 항체 작제물
AU2016250023B2 (en) Bispecific antibody constructs for CDH3 and CD3
JP7785450B2 (ja) Muc17及びcd3に向けられる二重特異性抗体コンストラクト
KR20210042117A (ko) Cldn18.2 및 cd3에 대한 항체 작제물
US20210238311A1 (en) Antibodies against phosphorylcholine
CN112500483B (zh) 抗血小板膜糖蛋白ib alpha人源化抗体及其应用
US20210230310A1 (en) Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
JP2026031952A (ja) 微小血管血栓症の処置のための標的化血栓溶解
JPWO2005007800A1 (ja) 抗血小板膜糖蛋白質viモノクローナル抗体
CN112996563A (zh) 靶向il-1r1和nlpr3的双特异性抗体
US20190315886A1 (en) Thrombin antibody, antigen-binding fragment and pharmaceutical use thereof
WO2006118350A1 (ja) 抗血小板膜糖蛋白質ⅵモノクローナル抗体
US11542329B2 (en) Antibodies targeting Glycoprotein VI
US20240067721A1 (en) Nanobody to glycoprotein vi
CA3188566A1 (en) Coagulation factor xi (fxi) binding protein
WO2023036815A1 (en) Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering
BR112020013018B1 (pt) Construto de anticorpo biespecífico, seu uso e composição farmacêutica
HK1199409B (en) Antibodies binding to phosphorylcholine (pc) and/or pc conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260312

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260512